BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32737246)

  • 1. Evaluation of
    Chodyla M; Demircioglu A; Schaarschmidt BM; Bertram S; Bruckmann NM; Haferkamp J; Li Y; Bauer S; Podleska L; Rischpler C; Forsting M; Herrmann K; Umutlu L; Grueneisen J
    J Nucl Med; 2021 Mar; 62(3):348-353. PubMed ID: 32737246
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Grueneisen J; Schaarschmidt B; Demircioglu A; Chodyla M; Martin O; Bertram S; Wetter A; Bauer S; Fendler WP; Podleska L; Forsting M; Herrmann K; Umutlu L
    J Nucl Med; 2019 Nov; 60(11):1537-1542. PubMed ID: 30926647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
    Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
    J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
    Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
    AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer.
    Goense L; Heethuis SE; van Rossum PSN; Voncken FEM; Lagendijk JJW; Lam MGEH; Terhaard CH; van Hillegersberg R; Ruurda JP; Mook S; van Lier ALHMW; Lin SH; Meijer GJ
    Nucl Med Commun; 2018 Jan; 39(1):60-67. PubMed ID: 29023336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan.
    Andreou D; Boldt H; Pink D; Jobke B; Werner M; Schuler M; Reichardt P; Tunn PU
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1076-83. PubMed ID: 24519553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.
    Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Mechtersheimer G; Schmitt T; Lehner B; Haberkorn U; Stroebel P; Kasper B
    J Nucl Med; 2010 Apr; 51(4):551-8. PubMed ID: 20351350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parameters of simultaneous 18F-FDG-PET/MRI predict tumor stage and several histopathological features in uterine cervical cancer.
    Surov A; Meyer HJ; Schob S; Höhn AK; Bremicker K; Exner M; Stumpp P; Purz S
    Oncotarget; 2017 Apr; 8(17):28285-28296. PubMed ID: 28423698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 3T diffusion-weighted MRI and
    Lee SY; Jee WH; Yoo IR; Jung JY; Im SA; Chung YG; Kang JH
    Br J Radiol; 2019 Oct; 92(1102):20181051. PubMed ID: 31322913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
    Evilevitch V; Weber WA; Tap WD; Allen-Auerbach M; Chow K; Nelson SD; Eilber FR; Eckardt JJ; Elashoff RM; Phelps ME; Czernin J; Eilber FC
    Clin Cancer Res; 2008 Feb; 14(3):715-20. PubMed ID: 18245531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
    Benz MR; Czernin J; Allen-Auerbach MS; Tap WD; Dry SM; Elashoff D; Chow K; Evilevitch V; Eckardt JJ; Phelps ME; Weber WA; Eilber FC
    Clin Cancer Res; 2009 Apr; 15(8):2856-63. PubMed ID: 19351756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.
    Denecke T; Hundsdörfer P; Misch D; Steffen IG; Schönberger S; Furth C; Plotkin M; Ruf J; Hautzel H; Stöver B; Kluge R; Bierbach U; Otto S; Beck JF; Franzius C; Henze G; Amthauer H
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1842-53. PubMed ID: 20505933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a connection between immunohistochemical markers and grading of lung cancer with apparent diffusion coefficient (ADC) and standardised uptake values (SUV) of hybrid 18F-FDG-PET/MRI?
    Martin O; Bruckmann NM; Kirchner J; Ullrich T; Ingenwerth M; Bogner S; Eze C; Nensa F; Herrmann K; Umutlu L; Antoch G; Sawicki LM
    J Med Imaging Radiat Oncol; 2020 Dec; 64(6):779-786. PubMed ID: 32705779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/MR imaging of lymphoma nodal target lesions: Comparison of PET standardized uptake value (SUV) with MR apparent diffusion coefficient (ADC).
    Bernstine H; Domachevsky L; Nidam M; Goldberg N; Abadi-Korek I; Shpilberg O; Groshar D
    Medicine (Baltimore); 2018 Apr; 97(16):e0490. PubMed ID: 29668631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Correlation of Prognostic Immunohistochemical Markers With SUV and ADC Derived From Dedicated Hybrid Breast 18F-FDG PET/MRI in Women With Newly Diagnosed Breast Cancer.
    Morawitz J; Kirchner J; Martin O; Bruckmann NM; Dietzel F; Li Y; Rischpler C; Herrmann K; Umutlu L; Bittner AK; Mohrmann S; Ingenwerth M; Häberle L; Esposito I; Antoch G; Buchbender C; Sawicki LM
    Clin Nucl Med; 2021 Mar; 46(3):201-205. PubMed ID: 33351505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial Staging of Locally Advanced Rectal Cancer and Regional Lymph Nodes: Comparison of Diffusion-Weighted MRI With 18F-FDG-PET/CT.
    Cerny M; Dunet V; Prior JO; Hahnloser D; Wagner AD; Meuli RA; Schmidt S
    Clin Nucl Med; 2016 Apr; 41(4):289-95. PubMed ID: 26828149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.
    Benz MR; Allen-Auerbach MS; Eilber FC; Chen HJ; Dry S; Phelps ME; Czernin J; Weber WA
    J Nucl Med; 2008 Oct; 49(10):1579-84. PubMed ID: 18794268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
    Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
    Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.